Abstract
The transport of the antiviral nucleoside analogue zidovudine (3′-azido-3′-deoxythymidine; AZT) into the central nervous system (CNS) was characterized in vitro and in vivo. The in vitro model consisted of primary cultures of isolated bovine capillary endothelial cells. The transport rate of AZT across the monolayer, expressed as endothelial permeability P, was determined following luminal and abluminal administration. P did not differ between the two administration sites (luminal, 1.65 ± 0.44 cm/min/103; abluminal, 1.63 ± 0.28 cm/min/103). The transport of AZT across the endothelial cell monolayer was found to be concentration independent in the range between 0.4 and 50 µg/mL. AZT transport was not affected by pre-treatment of the cells with either metabolic inhibitors (DODG and DODG/NaN3) or probenecid. This suggests that AZT passes the monolayer mainly by passive diffusion. The in vivo transport of AZT across the blood–brain barrier and the blood–CSF barrier was studied in male Wistar rats after coadministration of potential inhibitors of active transport of AZT: probenecid (organic anion transport) and thymidine (nucleoside transport). Intracerebroventricular and intravenous coadministration of probenecid caused a significant (P < 0.001) increase in the CSF/plasma concentration ratio compared to the control phase, indicating that the organic anion carrier is involved in AZT transport from CSF to blood. Since there was no effect of probenecid on the transport of AZT in vitro, it is suggested that this carrier is located at the choroid plexus. Coadministration of thymidine did not affect the CSF/plasma concentration ratio, suggesting that a nucleoside carrier system is not involved in AZT transport into or out of the CNS.
Similar content being viewed by others
REFERENCES
R. Yarchoan and S. Broder. Antiretroviral therapy of AIDS and related disorders: General principles and specific development of dideoxynucleosides. Pharmacol. Ther. 40:329–348 (1989).
R. Yarchoan, H. Mitsuya, C. E. Myers, et al. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N. Engl. J. Med. 321:726–738 (1989).
M. A. Fischl. State of antiretroviral therapy with zidovudine. AIDS 3 (Suppl. 1):S137–S143 (1989).
L. Resnick, J. R. Berger, P. Shapshak, et al. Early penetration of the blood-brain barrier by HIV. Neurology 38:9–14 (1988).
R. M. Levy, D. E. Bredesen, and M. L. Rosenblum. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): Experience at UCSF and review of the literature. J. Neurosurg. 62:475–495 (1985).
R. W. Price, B. Brew, J. Sidtis, et al. The brain in AIDS: Central nervous system HIV-I infection and AIDS dementia complex. Science 239:586–592 (1988).
C. Pedersen, C. Thomsen, P. Arlien-Soborg, et al. Central nervous system involvement in human immunodeficiency virus disease. Dan. Med. Bull. 38 (4):374–379 (1991).
P. Portegies, J. De Gans, J. M. A. Lange, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. Br. Med. J. 299:819–821 (1989).
R. E. Galinsky, B. L. Hoesterey, and B. D. Anderson. Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. Life Sci. 47:781–788 (1990).
A. R. Rachlis. Zidovudine (Retrovir) update. Can. Med. Assoc. J. 143 (11):1177–1185 (1990).
J. B. M. M. Van Bree, A. G. de Boer, M. Danhof, et al. Characterization of an “in vitro” blood-brain barrier: Effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J. Pharmacol. Exp. Ther. 3:1233–1239 (1988).
J. B. M. M. Van Bree, A. V. Baljet, A. Van Geyt, et al. The unit impulse response theory for the pharmacokinetic evaluation of drug entry into the central nervous system. J. Pharmacokin. Biopharm. 17:441–462 (1989).
K. L. Audus and R. T. Borchardt. Characterization of an in vitro blood-brain barrier model for studying drug transport and metabolism. Pharm. Res. 3:81–87 (1986).
J. B. M. M. Van Bree, D. L. Ypey, A. G. De Boer, et al. Trans-endothelial electrical resistance (TEER) of an in vitro blood-brain barrier: An indicator of drug permeability? (Submitted for publication).
W. C. Bowman and M. J. Rand. Drug treatment of viral infections. In W. C. Bowman and M. J. Rand (eds.), Textbook of Pharmacology, 2nd ed., Blackwell Scientific, London, 1980, p. 33.23.
M. Sittig (ed.). Handbook of Toxic and Hazardous Chemicals and Carcinogens, 2nd ed., Noyes, NJ, 1985.
R. Spector and A. V. Lorenzo. The effects of salicylate and probenecid on the cerebrospinal fluid transport of penicillin, aminosalicylic acid and iodide. J. Pharmacol. Exp. Ther. 188:55–65 (1974).
J. A. Cooper, P. J. Delvecchio, F. L. Minnear, et al. Measurement of albumin permeability across endothelial monolayers in vitro. J. Appl. Physiol. 62:1076–1083 (1987).
H. J. Bouman and T. B. Van Wimmersma Greidanus. A rapid and simple cannulation technique for repeated sampling of cerebrospinal fluid in freely moving rats. Brain Res. Bull. 4:575–577 (1979).
H. Benveniste and P. C. Huttemeier. Microdialysis-theory and application. Progr. Neurobiol. 35:195–215 (1990).
R. Kupferschmidt and R. W. Schmid. Specific routine determination of 3′-azido-3′-deoxythymidine (AZT) in plasma by partly automated liquid chromatography. Clin. Chem. 35:1313–1317 (1989).
H. Suzuki, Y. Sawada, Y. Sugiyama, et al. Transport of imipenem, a novel carbapenem antibiotic, in the rat central nervous system. J. Pharmacol. Exp. Ther. 250:979–984 (1988).
T. Terasaki and W. M. Pardridge. Restricted transport of 3′-azido-3′ deoxythymidine and dideoxynucleosides through the blood-brain barrier. J. Infect. Dis. 158:630–632 (1988).
R. Spector. Drug transport in the central nervous system: Role of carriers. Pharmacology 40:1–7 (1990).
R. Yarchoan, J. M. Pluda, C. F. Perno, et al. Initial clinical experience with dideoxynucleosides as single agents and in combination therapy. Ann. N.Y. Acad. Sci. 616:328–343 (1990).
R. J. Sawchuk and M. A. Hedaya. Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1. Effect of probenecid. Pharm. Res. 7 (4):332–338 (1990).
M. A. Hedaya, W. F. Elmquist, and R. J. Sawchuk. Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers. Pharm. Res. 7:411–417 (1990).
P. De Miranda, T. C. Burnette, and S. Good. Tissue distribution and metabolic disposition of zidovudine in rats. Drug Metab. Dis. 18:315–320 (1989).
M. A. Hedaya and R. J. Sawchuk. Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit. J. Pharm. Sci. 78:716–722 (1989).
B. G. Petty, D. M. Kornhauser, and P. S. Lietman. Zidovudine with probenecid: A warning. Lancet 1044–1045 (1990).
R. Spector. Thymidine transport in the central nervous system. J. Neurochem. 35:1092–1098 (1980).
R. Spector and W. G. Berlinger. Localization and mechanism of thymidine transport in the central nervous system. J. Neurochem. 39:837–841 (1982).
E. M. Cornford and W. H. Oldendorf. Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim. Biophys. Acta 394:211–219 (1975).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Masereeuw, R., Jaehde, U., Langemeijer, M.W.E. et al. In Vitro and in Vivo Transport of Zidovudine (AZT) Across the Blood–Brain Barrier and the Effect of Transport Inhibitors. Pharm Res 11, 324–330 (1994). https://doi.org/10.1023/A:1018932213953
Issue Date:
DOI: https://doi.org/10.1023/A:1018932213953